BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, is seeking a pre-revenue listing on the Hong Kong Stock Exchange (HKEX) to raise capital to advance its BTK inhibitor, ICP-022, to an NDA filing in China by the end of this year.
HONG KONG – South Korea's Helixmith Co. Ltd. has announced the results of a phase III trial extension testing VM-202 (donaperminogene seltoplasmid), a regenerative plasmid DNA gene therapy candidate, in diabetic peripheral neuropathy (DPN).
HONG KONG – South Korea's biopharmaceutical venture Genome & Co. Ltd. recently secured KRW30.2 billion (US$25.2 million) in series C investment with an IPO and global clinical trial plans for next year.
HONG KONG – Upin & Co. Ltd., a fund and asset management company headquartered in London, plans to invest a total of KRW2 trillion (US$1.7 billion) over three years in the South Korean biopharma industry.
HONG KONG – Kobiolabs Inc., a microbiome-based venture from Seoul, South Korea, has secured a KRW26.6 billion (US$22.2 million) investment. Founded in 2014, the venture has achieved KRW193 billion of enterprise value.
Australian researchers have developed the first potent new small-molecule inhibitors capable of blocking the activation of apoptotic cell death before it causes damage to mitochondria, they reported in a study published in the Oct. 7, 2019, issue of Nature Chemical Biology.
Days after going public, Viela Bio Inc. nailed down a deal with Mitsubishi Tanabe Pharma Corp. to develop and commercialize Viela’s humanized anti-CD19 monoclonal antibody, inebilizumab, in nine Asia regions for the rare disease called neuromyelitis optica spectrum disorder (NMOSD), as well as other potential future indications.
HONG KONG – South Korean pharmaceutical company Chong Kun Dang Holdings recently invested KRW5 billion (US$4.1 million) in Biorchestra Co. Ltd., a Korean startup based in Daejeon that aims to develop Alzheimer’s dementia treatment based on microRNA.
HONG KONG – Taiwan's National Health Insurance Administration has added Gilead Sciences Inc.'s Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), a once-daily single tablet for the treatment of adults with HIV-1, to its list of reimbursed medicines.
HONG KONG – I-Mab Biopharma (Shanghai) Co. Ltd. has received IND approval from China's National Medical Products Administration (NMPA) for its CD73 antibody, getting the go-ahead for a phase I/II trial of TJD-5 in patients with advanced solid tumors.